Wireva

Antifungal therapy alters gut microbiome and eases inflammatory bowel disease activity

A prospective observational study in Nature Medicine finds that fluconazole, but not nystatin, improves microbiome dynamics and reduces disease activity in inflammatory bowel disease patients with oral thrush after eight weeks.

Antifungal therapy improves microbiome dynamics in inflammatory bowel disease
Antifungal therapy alters gut microbiome and eases inflammatory bowel disease activity
Human microbiome · Wikimedia — licence per file · rights

This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.

Monitoring item. The full text is not distributed. Extract and source below.

A prospective observational study in Nature Medicine finds that fluconazole, but not nystatin, improves microbiome dynamics and reduces disease activity in inflammatory bowel disease patients with oral thrush after eight weeks.